W1020

W146 hydrate

≥98% (HPLC)

• Synonym(e): ML056, R-3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid hydrate, [(3R)-3-amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid
• Empirische Formel (Hill-System): C₁₆H₂₇N₂O₄P · xH₂O
• CAS-Nummer: 909725-61-7
• Molekulargewicht: 342.37 (anhydrous basis)
• MDL-Nummer: MFCD16875441
• UNSPSC-Code: 12352211
• PubChem Substanz-ID: 329830425
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: off-white
• Löslichkeit: methanol: soluble (with 0.1% TFA)
• Ersteller: Novartis
• Lagertemp.: 2-8°C
• SMILES String: O.CCCCCCc1cccc(NC(=O)[C@H](N)CCP(O)(O)=O)c1
• InChI: 1S/C16H27N2O4P.H2O/c1-2-3-4-5-7-13-8-6-9-14(12-13)18-16(19)15(17)10-11-23(20,21)22;/h6,8-9,12,15H,2-5,7,10-11,17H2,1H3,(H,18,19)(H2,20,21,22);1H2/t15-;/m1./s1
• InChIKey: DQKSZHVSROOTFY-XFULWGLBSA-N

Beschreibung

Allgemeine Beschreibung

W146 hydrate functions as an orthosteric antagonist. It is associated with blood lymphopenia and lung edema in mice.

Anwendung

W146 hydrate has been used to assess vascular permeability in mice.

Biochem./physiol. Wirkung

Potent S1P(1) competitive antagonist; Ki = 10-77 nM.

Leistungsmerkmale und Vorteile

This compound is featured on the Lysophospholipid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable